Genincode PLC
LSE:GENI
Operating Margin
Genincode PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
UK |
G
|
Genincode PLC
LSE:GENI
|
5.2m GBP |
-185%
|
|
US |
![]() |
Cigna Corp
NYSE:CI
|
80B USD |
4%
|
|
US |
C
|
Cigna Group
XMUN:CGN
|
67.9B EUR |
4%
|
|
US |
![]() |
CVS Health Corp
NYSE:CVS
|
76.6B USD |
3%
|
|
DE |
![]() |
Fresenius Medical Care AG
XMUN:FME
|
26.9B EUR |
7%
|
|
DE |
![]() |
Fresenius SE & Co KGaA
XETRA:FRE
|
23.7B EUR |
9%
|
|
US |
![]() |
Laboratory Corporation of America Holdings
NYSE:LH
|
22.2B USD |
9%
|
|
US |
![]() |
Quest Diagnostics Inc
NYSE:DGX
|
19B USD |
14%
|
|
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
13.5B EUR |
7%
|
|
US |
![]() |
Hims & Hers Health Inc
NYSE:HIMS
|
12.9B USD |
6%
|
|
US |
![]() |
DaVita Inc
NYSE:DVA
|
11.2B USD |
15%
|
Genincode PLC
Glance View
GENinCode UK Ltd. engages in the risk assessment and prediction of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2021-07-22. The firm develops patented deoxyribonucleic acid (DNA) risk assessment products which utilize artificial intelligence (AI), bioinformatics and a globally recognized clinical evidence base to provide predictive analysis of a patient’s health risk. The Company’s clinical diagnostic tests cover global disease areas such as cardiovascular, cancer and diabetes.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Genincode PLC's most recent financial statements, the company has Operating Margin of -184.6%.